The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 24 results:
Author Title Type [ Year(Asc)]
Filters: Author is Psyrri, Amanda  [Clear All Filters]
2020
Fountzilas, E., Kotoula V., Koliou G-A., Giannoulatou E., Gogas H., Papadimitriou C., et al. (2020).  Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative.. Oncotarget. 11(1), 1-14.
Chatzopoulos, K., Kotoula V., Manoussou K., Markou K., Vlachtsis K., Angouridakis N., et al. (2020).  Tumor Infiltrating Lymphocytes and CD8+ T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma.. Head Neck Pathol. 14(3), 689-700.
2019
Carvajal-Hausdorf, D. E., Patsenker J., Stanton K. P., Villarroel-Espindola F., Esch A., Montgomery R. R., et al. (2019).  Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry.. Clin Cancer Res. 25(10), 3054-3062.
Lazaridis, G., Kotoula V., Vrettou E., Kostopoulos I., Manousou K., Papadopoulou K., et al. (2019).  Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer.. Cancer Genomics Proteomics. 16(3), 195-206.
Fountzilas, E., Kotoula V., Pentheroudakis G., Manousou K., Polychronidou G., Vrettou E., et al. (2019).  Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer.. ESMO Open. 4(2), e000474.
2018
Koutras, A., Lazaridis G., Koliou G-A., Kouvatseas G., Christodoulou C., Pectasides D., et al. (2018).  Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.. PLoS One. 13(12), e0207707.
Fountzilas, G., Psyrri A., Giannoulatou E., Tikas I., Manousou K., Rontogianni D., et al. (2018).  Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.. Int J Cancer. 142(1), 66-80.
Fountzilas, E., Kotoula V., Tikas I., Manousou K., Papadopoulou K., Poulios C., et al. (2018).  Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer.. Oncotarget. 9(86), 35623-35638.
2017
Psyrri, A., Kalogeras K. T., Wirtz R. M., Kouvatseas G., Karayannopoulou G., Goussia A., et al. (2017).  Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.. J Transl Med. 15(1), 30.
2016
Vassilakopoulou, M., Avgeris M., Velcheti V., Kotoula V., Rampias T., Chatzopoulos K., et al. (2016).  Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.. Clin Cancer Res. 22(3), 704-13.
Gogas, H., Kotoula V., Alexopoulou Z., Christodoulou C., Kostopoulos I., Bobos M., et al. (2016).  MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.. J Transl Med. 14(1), 136.
Kotoula, V., Lakis S., Vlachos I. S., Giannoulatou E., Zagouri F., Alexopoulou Z., et al. (2016).  Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes.. PLoS One. 11(9), e0163138.
Kotoula, V., Chatzopoulos K., Lakis S., Alexopoulou Z., Timotheadou E., Zagouri F., et al. (2016).  Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.. Oncotarget. 7(4), 5074-87.
2015
Kotoula, V., Bobos M., Vassilakopoulou M., Tsolaki E., Chrisafi S., Psyrri A., et al. (2015).  Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).. Appl Immunohistochem Mol Morphol. 23(1), 60-70.
Carvajal-Hausdorf, D. E., Schalper K. A., Pusztai L., Psyrri A., Kalogeras K. T., Kotoula V., et al. (2015).  Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.. J Natl Cancer Inst. 107(8), 
Pavlakis, K., Bobos M., Batistatou A., Kotoula V., Eleftheraki A. G., Stofas A., et al. (2015).  p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.. Pathol Oncol Res. 21(2), 273-82.
2014
Razis, E., Pentheroudakis G., Rigakos G., Bobos M., Kouvatseas G., Tzaida O., et al. (2014).  EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.. J Cancer Res Clin Oncol. 140(5), 737-48.
Vassilakopoulou, M., Togun T., Dafni U., Cheng H., Bordeaux J., Neumeister V. M., et al. (2014).  In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.. PLoS One. 9(6), e99131.
Pectasides, E., Rampias T., Sasaki C., Perisanidis C., Kouloulias V., Burtness B., et al. (2014).  Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC).. PLoS One. 9(4), e94273.
Psyrri, A., Lee J-W., Pectasides E., Vassilakopoulou M., Kosmidis E. K., Burtness B. A., et al. (2014).  Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.. Clin Cancer Res. 20(11), 3023-32.
Psyrri, A., Kotoula V., Fountzilas E., Alexopoulou Z., Bobos M., Televantou D., et al. (2014).  Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer.. Oral Oncol. 50(4), 298-305.
2011
Pectasides, E., Rampias T., Kountourakis P., Sasaki C., Kowalski D., Fountzilas G., et al. (2011).  Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma.. Clin Cancer Res. 17(9), 2947-54.
2010
Pectasides, E., Egloff A-M., Sasaki C., Kountourakis P., Burtness B., Fountzilas G., et al. (2010).  Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.. Clin Cancer Res. 16(8), 2427-34.
2009
Pectasides, D., Fountzilas G., Papaxoinis G., Pectasides E., Xiros N., Sykiotis C., et al. (2009).  Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.. Int J Gynecol Cancer. 19(4), 777-81.

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.